Login / Signup

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma.

Zahra GoudarziRahil Sadat ShahtaheriZhila NajafpourHaleh HamedifarHamidreza Ebrahimi
Published in: Cost effectiveness and resource allocation : C/E (2024)
DRd triplet therapy compared to KRd is a cost-effective regimen for RRMM under Iran willingness-to-pay threshold.
Keyphrases
  • multiple myeloma
  • low dose
  • high dose
  • health insurance
  • energy transfer
  • cell therapy